S H Kelkar and Company Analyst Review May 2026

This S H Kelkar and Company analyst review for May 2026 covers all critical data investors need for SHK at Rs 136.32. S H Kelkar is India’s largest flavour and fragrance company. This S H Kelkar and Company analyst review analyses technical levels, business fundamentals, valuation, and key risks for SHK through FY27.

Click Here – Get Free Investment Predictions

S H Kelkar and Company Analyst Review: Company Snapshot May 2026

SH Kelkar’s Keva brand fragrances, home care, and personal care fragrance ingredients serve FMCG, cosmetics, and household product companies in India and globally. The table below summarises key metrics for this S H Kelkar and Company analyst review.

Parameter	Value
NSE Ticker	SHK
Sector	Specialty Chemicals – Flavours and Fragrances
CMP (May 2026)	Rs 136.32
52 Week High	Rs 163.58
52 Week Low	Rs 109.06
Market Cap	Rs 3500 Crore
Trailing P/E	35x
Analyst Consensus Target	Rs 170.40
Bull Case Target	Rs 211.30
Bear Case Target	Rs 115.87

Analyst Insight: S H Kelkar and Company Analyst Review for FY27

Senior Research Analyst Ankit Jaiswal flags S H Kelkar and Company as a stock to watch in May 2026. At Rs 136.32, Ankit Jaiswal identifies key support in the Rs 111.24 to Rs 129.50 band and resistance near Rs 144.50. He suggests watching S H Kelkar and Company for a potential move toward Rs 170.40. Ankit Jaiswal’s view in this S H Kelkar and Company analyst review does not constitute a trade recommendation.

Technical Analysis in This S H Kelkar and Company Analyst Review

This S H Kelkar and Company analyst review places SHK at Rs 136.32 within its 52-week band of Rs 109.06 to Rs 163.58. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating SHK.

The S H Kelkar and Company analyst review identifies support in the Rs 111.24 to Rs 129.50 range and resistance in the Rs 144.50 to Rs 153.36 zone. A sustained close above Rs 144.50 could signal momentum toward the analyst consensus target of Rs 170.40.

Screen the best stocks on the Univest Screener.

Support and Resistance in This S H Kelkar and Company Analyst Review

• Support Zone: Rs 111.24 to Rs 129.50 – this S H Kelkar and Company analyst review identifies this as a potential accumulation signal for SHK.
• Resistance Zone: Rs 144.50 to Rs 153.36 – the S H Kelkar and Company analyst review flags a close above Rs 144.50 as a positive signal for SHK.
• Consensus Target: Rs 170.40 is the base-case target in this S H Kelkar and Company analyst review.

Business Segments in This S H Kelkar and Company Analyst Review

Fragrance Ingredients and Compounds

This primary segment drives revenue and margin for S H Kelkar and Company, supporting the earnings trajectory toward Rs 170.40 in this S H Kelkar and Company analyst review.

Home Care and Personal Care Fragrances

This segment adds meaningful scale to S H Kelkar and Company’s model and is a key EPS contributor through FY27 as identified in this S H Kelkar and Company analyst review.

Export to Global FMCG Companies

This growth frontier is a potential re-rating catalyst for SHK and a key element of this S H Kelkar and Company analyst review.

Valuation: S H Kelkar and Company Analyst Review Bull Bear Base Case

At Rs 136.32 and P/E of 35x, this S H Kelkar and Company analyst review sets three scenarios: bull case Rs 211.30, base case Rs 170.40, and bear case Rs 115.87.

Scenario	Target Price	Key Condition
Bull Case	Rs 211.30	Strong FY27 delivery and Specialty Chemicals – Flavours and Fragrances re-rating
Base Case	Rs 170.40	Moderate growth per analyst consensus in this S H Kelkar and Company analyst review
Bear Case	Rs 115.87	Earnings miss or macro headwinds for SHK

FY27 Outlook in This S H Kelkar and Company Analyst Review

This S H Kelkar and Company analyst review for FY27 is constructive provided SHK delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Specialty Chemicals – Flavours and Fragrances indicators, RBI policy, and FII flow trends.

Key Risks in This S H Kelkar and Company Analyst Review

This S H Kelkar and Company analyst review identifies four key risks for SHK: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: S H Kelkar and Company Analyst Review Verdict May 2026

This S H Kelkar and Company analyst review concludes that SHK at Rs 136.32 presents a defined risk-reward with consensus target Rs 170.40. The 52-week range of Rs 109.06 to Rs 163.58 provides further context. Use this S H Kelkar and Company analyst review as a research reference and consult a SEBI-registered advisor before investing in SHK.

FAQs: S H Kelkar and Company Analyst Review 2026

What is the analyst target for S H Kelkar and Company in 2026?

The S H Kelkar and Company analyst review consensus target is Rs 170.40, bull case Rs 211.30, bear case Rs 115.87.

Is S H Kelkar and Company a good buy at Rs 136.32?

At Rs 136.32 with PE 35x and target Rs 170.40, this S H Kelkar and Company analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this S H Kelkar and Company analyst review.

What is the 52-week high and low of S H Kelkar and Company?

52-week high is Rs 163.58 and 52-week low is Rs 109.06. This S H Kelkar and Company analyst review contextualises SHK at Rs 136.32 within this range.

What are the key risks for S H Kelkar and Company?

Key risks in this S H Kelkar and Company analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Specialty Chemicals – Flavours and Fragrances sector.

Where can I track live data for S H Kelkar and Company?

Track S H Kelkar and Company’s live price on the Univest Screener to complement this S H Kelkar and Company analyst review with real-time data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.